Anteris technologies global corp美股招股说明书(2026-01-20版)

The information in this preliminary prospectus supplement is not complete and may bechanged. This preliminary prospectus supplement and the accompanying prospectus are notan offer to sell these securities and are not soliciting an offer to buy these securities in any Filed Pursuant to Rule424(b)(5)Registration No. 333-292565 SUBJECT TO COMPLETION, DATED JANUARY 20, 2026 PRELIMINARY PROSPECTUS SUPPLEMENTTo Prospectus, dated January8, 2026 Anteris Technologies Global Corp. Common Stock We are offering $200,000,000 of shares of our common stock, par value $0.0001 per share (“Common Stock”), pursuant tothis prospectus supplement and the accompanying prospectus. The public offering price for each share of Common Stock is Concurrently with this offering, pursuant to a stock purchase agreement dated January 20, 2026 (the “Stock PurchaseAgreement”), we have agreed to sell to Covidien Group S.à r.l., a wholly-owned subsidiary of Medtronic plc (the “Investor”),up to $90.0 million of shares of Common Stock, subject to a minimum purchase of 16.0% of the number of shares ofCommon Stock outstanding after this offering and such issuance to the Investor (the “Private Placement”) and a maximumpurchase of 19.99% of the number of shares of Common Stock outstanding after this offering, at a price per share equal to thepublic offering price in this offering. The Private Placement is being conducted pursuant to the exemption provided under Our Common Stock is listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “AVR.” Our CHESS DepositaryInterests over our Common Stock (“CDIs”) trade on the Australian Securities Exchange (the “ASX”) under the symbol Investing in our Common Stock involves a high degree of risk. See the sections titled “Risk Factors” beginning on pageS-8of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement and (1)See the section of this prospectus supplement titled “Underwriting” for additional disclosure regarding underwriting discounts,commissions and expenses. We have granted the underwriters an option to purchase up to an additional $30,000,000 of shares of Common Stock,exercisable within a 30-day period, at the public offering price, less underwriting discounts and commissions. * in alphabetical order TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement describes the specific terms of this offering and adds to and updates informationcontained in the accompanying prospectus. The accompanying prospectus provides more general information, someof which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to thisprospectus supplement and the accompanying prospectus combined. To the extent there is a conflict between the This prospectus forms a part of a registration statement on FormS-3 that we have filed with the Securities andExchange Commission (the “SEC”) utilizing a “shelf” registration process. You should read this prospectus and therelated exhibits filed with the SEC, together with the additional information described under the headings “Where Neither we nor the underwriters have authorized anyone to provide you with any information other than theinformation contained or incorporated by reference in this prospectus supplement or the accompanying prospectus orany free writing prospectus prepared by or on behalf of us in connection with this offering to which we have referredyou. We and the underwriters take no responsibility for, and can provide no assurances as to the reliability of, anyother information that others may give you. The information contained in this prospectus supplement or theaccompanying prospectus, or incorporated by reference herein or therein, or in any such free writing prospectusprovided in connection with this offering is accurate only as of the date thereof, regardless of the time of delivery ofsuch document or of any sale of our Common Stock. Our business, financial condition and results of operations may Neither we nor the underwriters are offering to sell, or seeking offers to buy, our Common Stock in any jurisdictionswhere offers and sales are not permitted. The distribution of this prospectus supplement and the accompanyingprospectus and the offering of our Common Stock in certain jurisdictions may be restricted by law. Persons outsidethe United States who come into possession of this prospectus supplement and the accompanying prospectus mustinform themselves about, and observe any restrictions relating to, the offering of our Common Stock and thedistribution of this prospectus outside the United States. This prospectus supplement and the accompanying In this prospectus supplement, unless otherwise indicated or the context otherwise requires, all references in thisprospectus to the “Company,” “Anteris,” “Anteris®,” “we,” “us” and “our” refer to Anteris Technologies Pty Ltd(formerly Anteris Technologies Ltd) (“ATPL”) prior to the Reorg